Business
Exscientia enters collaboration with Bayer AG
Exscientia enters collaboration with Bayer AG.
About this update from Frontier Ip Group Plc
[{"type":"text","content":"\n \nRNS Number : 3680Z Frontier IP Group plc 10 January 2020 \n\nRNS Reach\nAIM: FIPP\n10 January 2020\n \n \nFrontier IP Group Plc\n(\"Frontier IP\" or the \"Group\")\n \nPortfolio news - Exscientia enters collaboration with Bayer AG to leverage the potential of Artificial Intelligence (\"AI\") in cardiovascular and oncology drug discovery\n \n \nFrontier IP, a specialist in commercialising university intellectual property, is pleased to note that portfolio company Exscientia (\"Exscientia\" or the \"Company\"), a world leader in AI-driven drug discovery, that it has entered into a collaboration with Bayer AG focused on cardiovascular disease and oncology. \n \nUnder the terms of the agreement, Exscientia may be eligible to receive up to €240 million including upfront and research payments, and for meeting near term and clinical milestones. The Company may also receive sales royalties.\n \nExscientia's other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron, Rallybio and Evotec. Frontier IP currently holds a 3.25 per cent stake in the Company. \n \n \nExscientia statement in full:\n \nBAYER AND EXSCIENTIA COLLABORATE TO LEVERAGE THE POTENTIAL OF ARTIFICIAL INTELLIGENCE IN CARDIOVASCULAR AND ONCOLOGY DRUG DISCOVERY \n \nExscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.\n \nUnder terms of the agreement, Exscientia will initially work on three projects with targets agreed between both parties. Exscientia may be eligible to receive up to €240 Million, including upfront and research payments, near term and clinical milestones. As part of the agreement, Exscientia may also receive sales royalties.\n \nProfessor Andrew Hopkins, CEO of Exscientia, commented: \"We're delighted to collaborate with Bayer, a globally recognised pharmaceutical company. Since our pioneering Nature papers demonstrating the automated design of small-molecules, we have enhanced our platform and exemplified it commercially, by accelerating the discovery of future drug molecules with partners.\"\n \nDr. Joerg Moeller, Member of the Executive Com...